Experts' discussion

How to tackle parasitic worms

Parasitic worm infections – or helminthiases – affect more than one billion people and have a considerable public health impact in many parts of the world.

In December 2017, international experts gather in Basel, Switzerland, to discuss new strategies to control and eliminate parasitic worms. The scientific symposium is hosted by the Swiss Tropical and Public Health Institute. Approximately 1.5 billion people globally are affected by soil-transmitted helminthiasis and another 250 million suffer from schistosomiasis; two of the most common parasitic worm infections. They are transmitted by different species of parasitic worms in the soil or water and can result in diarrhoea, malnutrition, impaired growth and enlargement of the liver or spleen. The morbidity caused by chronic helminth infections can debilitate entire communities and contribute to poverty in endemic areas.

Source: Shutterstock/Juan Gaertner

160 scientists gather in Basel

To review current strategies and to discuss new ways of preventing, controlling and eliminating helminth infections, the Swiss Tropical and Public Health Institute (Swiss TPH) is hosting a two-day symposium in Basel, Switzerland. Over 160 scientists and experts are on hand to critically review innovations in diagnostics and drugs and to discuss control strategies to interrupt transmission of parasitic worm infections. One presentation will show results from Zanzibar that demonstrate how a multifaceted intervention package can reduce prevalence of infection among school-aged children to less than 2%.

“Although parasitic worms affect one out of five people worldwide, they belong to the so-called neglected tropical diseases, which are intimately linked to poverty,” says Jürg Utzinger, Director of Swiss TPH. “While we see certain progress, we need to further foster innovation, refine existing tools and strategies and employ integrated control approaches that are tailored to social-ecological contexts.”

“New drugs urgently needed”

There is a pressing need to discover and develop new drugs and rigorously evaluate potential combination therapies

Jennifer Keiser

Innovations are urgently needed in drug discovery and development. “Our research indicates that efficacy of current anthelminthic drugs is declining,” says Jennifer Keiser, Head of the Helminth Drug Development Unit at Swiss TPH and recently appointed Associate Professor of Neglected Tropical Diseases at the University of Basel. “Hence, there is a pressing need to discover and develop new drugs and rigorously evaluate potential combination therapies. This symposium is a terrific opportunity for Swiss TPH to showcase our existing partnerships and to develop new collaborations.”


Source: Swiss Tropical and Public Health Institute

08.12.2017

Read all latest stories

Related articles

Point-of-care testing

Moving towards deeper diagnostics with POCT

Just two decades ago, even though promising, point-of-care testing (POCT) was only used in hospitals and surgeries by a small number of specialists. Today POCT is in use throughout healthcare.

ECCMID

Antibiotic combination against multidrug-resistant pathogens

Gram-negative pathogens are responsible for half of all healthcare-associated infections and their ability to resist traditional antibiotics makes them more dangerous for seriously ill patients in a…

Hygiene and microbiology meeting

No all clear for nosocomial infections

Experts at the 70th Annual Meeting of the German Society for Hygiene and Microbiology, held in Bochum, exchanged information on newly discovered resistances. ‘Specifically, resistance against a…

Related products

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd